Literature DB >> 10529140

Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures.

D Mitra1, D M Elvins, A J Collins.   

Abstract

OBJECTIVE: To determine the relationship of biochemical markers of bone metabolism in patients with mild ankylosing spondylitis (AS) with disease activity, bone mineral density (BMD), and vertebral fractures.
METHODS: A total of 56 male patients with mild AS were studied. All patients had BMD measured by dual x-ray absorptiometry of the lumbar spine and hip and radiographs of the thoracic and lumbar spines. Radiographs of patients with AS were evaluated morphometrically and vertebral fractures were defined using established criteria. Serum osteocalcin, total and bone alkaline phosphatase (ALP, BALP, respectively), 25-hydroxyvitamin D (25-OHD), parathyroid hormone (PTH), urinary deoxypyridinoline (Dpyr), and pyridinoline (Pyr) were measured in the patients with AS and compared with 52 age and sex matched controls. Thirty-nine healthy male subjects aged 50-60 years, recruited from primary care registers, had spinal radiographs and served as controls for vertebral fractures.
RESULTS: Patients with AS had reduced BMD of the lumbar spine, 0.98 (0.1) g/cm2 [T score = -1.14 (1.2) and Z score = -1.01 (1.2)], and femoral neck, 0.83 (0.1) g/cm2 [T score = -1.44 (1.2) and Z score = -0.73 (1.1)]. Of the 56 patients with AS, 11 (19.6%) had a vertebral fracture, whereas only one of 39 control subjects did (2.6%). Patients with AS had significantly lower mean serum osteocalcin compared with controls [9.03 (2.7) microg/l vs 11.05 (2.33) microg/l; p < 0.001], and significantly higher mean serum ALP [73.09 (19.5) U/l vs 53.02 (16.7) U/l; p < 0.001] and BALP [38.54 (9.9) U/l vs 30.35 (8.28) U/l; p < 0.001]. There was no significant difference in the excretion of Dpyr and Pyr between patients with AS and controls [4.90 (3.9) nmol/mmol vs 4.00 (3.6) nmol/mmol, and 15.66 (10.8) nmol/mmol vs 12.24 (10.3) nmol/mmol, respectively]. There were no significant differences in the mean 25-OHD and PTH levels in patients with AS compared to controls [20.03 (1.6) micromol/l vs 18.9 (2.9) micromol/l and 3.31 (1.5) pmol/l vs 2.63 (0.4) pmol/l, respectively]. The biochemical markers of bone formation and resorption correlated well with inflammatory indices of disease activity (acute phase reactants), but not with BMD of the lumbar spine or femoral neck. No significant difference was seen in any marker of bone turnover when AS patients with vertebral fractures were compared with those without.
CONCLUSION: Bone turnover in patients with mild AS is characterized by low serum osteocalcin and ALP in the presence of normal calciotropic hormones. Biochemical markers of bone metabolism do not correlate with BMD or vertebral fractures. The disparity between osteocalcin and alkaline phosphatase in patients with AS needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529140

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Biomarkers in spondyloarthritis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

2.  Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis.

Authors:  Laura Muntean; Marena Rojas-Vargas; Pilar Font; Siao-Pin Simon; Simona Rednic; Ruxandra Schiotis; Simona Stefan; Maria M Tamas; Horatiu D Bolosiu; Eduardo Collantes-Estévez
Journal:  Clin Rheumatol       Date:  2011-01-11       Impact factor: 2.980

Review 3.  [Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].

Authors:  H Franck; J Braun; F Buttgereit; W Demary; G Hein; J Kekow; G Schett; P M Kern
Journal:  Z Rheumatol       Date:  2009-12       Impact factor: 1.372

4.  A 2-year longitudinal study of bone health in adolescent patients with axial spondyloarthritis.

Authors:  Shin-Hee Kim; Ki Hwan Kim; Moon-Young Kim; Yeon Sik Hong; Kwi Young Kang
Journal:  Arch Osteoporos       Date:  2021-01-08       Impact factor: 2.617

Review 5.  Bone Involvement in Patients with Spondyloarthropathies.

Authors:  Willem Lems; Corinne Miceli-Richard; Judith Haschka; Andrea Giusti; Gitte Lund Chistensen; Roland Kocijan; Nicolas Rosine; Niklas Rye Jørgensen; Gerolamo Bianchi; Christian Roux
Journal:  Calcif Tissue Int       Date:  2022-01-23       Impact factor: 4.333

6.  Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT): 10-year follow-up.

Authors:  Mariusz Korkosz; Jerzy Gąsowski; Piotr Grzanka; Janusz Gorczowski; Wojciech Pluskiewicz; Sławomir Jeka; Tomasz Grodzicki
Journal:  BMC Musculoskelet Disord       Date:  2011-05-31       Impact factor: 2.362

Review 7.  Paget's disease of bone: an osteoimmunological disorder?

Authors:  Mohamed S Numan; Nathalie Amiable; Jacques P Brown; Laëtitia Michou
Journal:  Drug Des Devel Ther       Date:  2015-08-14       Impact factor: 4.162

8.  Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Zhongchao Fu; Zhizhong Ye
Journal:  Arch Rheumatol       Date:  2016-04-15       Impact factor: 1.472

9.  Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

Authors:  S Visvanathan; D van der Heijde; A Deodhar; C Wagner; D G Baker; J Han; J Braun
Journal:  Ann Rheum Dis       Date:  2008-05-21       Impact factor: 19.103

10.  Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.

Authors:  Heiner Appel; Louise Janssen; Joachim Listing; René Heydrich; Martin Rudwaleit; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2008-10-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.